Cristiana Gaiteiro

Porto, 4200072, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy.

A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: December 17, 2023

Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.

Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.

Journal: iScience

Published: November 27, 2023

MicroRNA Biomarkers as Promising Tools for Early Colorectal Cancer Screening-A Comprehensive Review.

MicroRNA Biomarkers as Promising Tools for Early Colorectal Cancer Screening-A Comprehensive Review.

Journal: International journal of molecular sciences

Published: June 09, 2023

Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.

Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.

Journal: Theranostics

Published: September 23, 2021

Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 15, 2021

Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells.

Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells.

Journal: Cancers

Published: February 20, 2020

CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications.

CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications.

Journal: Clinical proteomics

Published: May 23, 2018

Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications.

Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications.

Journal: New biotechnology

Published: April 22, 2018

Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer.

Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer.

Journal: Talanta

Published: December 27, 2017

Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.

Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases.

Journal: Urologic oncology

Published: August 11, 2017

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Journal: Oncotarget

Published: March 13, 2017

Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.

Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.

Journal: Molecular oncology

Published: October 15, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026